MENU
+Compare
DXCM
Stock ticker: NASDAQ
AS OF
Jan 14, 04:59 PM (EDT)
Price
$69.70
Change
-$0.55 (-0.78%)
Capitalization
27.4B

DXCM DexCom Forecast, Technical & Fundamental Analysis

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients... Show more

DXCM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for DXCM with price predictions
Jan 13, 2026

DXCM's RSI Oscillator peaks and leaves overbought zone

The 10-day RSI Oscillator for DXCM moved out of overbought territory on January 08, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 instances where the indicator moved out of the overbought zone. In of the 38 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 61 cases where DXCM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXCM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

DXCM broke above its upper Bollinger Band on January 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 12, 2026. You may want to consider a long position or call options on DXCM as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for DXCM just turned positive on January 06, 2026. Looking at past instances where DXCM's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for DXCM crossed bullishly above the 50-day moving average on December 09, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DXCM advanced for three days, in of 305 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 245 cases where DXCM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DXCM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.050) is normal, around the industry mean (62.991). P/E Ratio (39.028) is within average values for comparable stocks, (38.209). Projected Growth (PEG Ratio) (0.924) is also within normal values, averaging (1.662). DXCM has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (6.337) is also within normal values, averaging (39.712).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXCM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
DXCM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

DXCM is expected to report earnings to rise 5.98% to 64 cents per share on February 12

DexCom DXCM Stock Earnings Reports
Q4'25
Est.
$0.65
Q3'25
Beat
by $0.04
Q2'25
Beat
by $0.03
Q1'25
Missed
by $0.01
Q4'24
Missed
by $0.07
The last earnings report on October 30 showed earnings per share of 61 cents, beating the estimate of 56 cents. With 2.72M shares outstanding, the current market capitalization sits at 27.40B.
A.I. Advisor
published General Information

General Information

a maker of medical devices and glucose monitoring systems

Industry MedicalNursingServices

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
6340 Sequence Drive
Phone
+1 858 200-0200
Employees
9600
Web
https://www.dexcom.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MGNR47.100.12
+0.26%
American Beacon GLG Natrl Res ETF
BFRZ27.03N/A
N/A
Innovator Equity Managed 100 Buffer ETF
NVBW34.12N/A
-0.01%
AllianzIM US Equity Buffer20 Nov ETF
FLIN37.93-0.29
-0.76%
Franklin FTSE India ETF
DAT44.66-0.59
-1.31%
ProShares Big Data Refiners ETF

DXCM and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, DXCM has been loosely correlated with ISRG. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if DXCM jumps, then ISRG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DXCM
1D Price
Change %
DXCM100%
-1.03%
ISRG - DXCM
46%
Loosely correlated
-1.91%
ALGN - DXCM
44%
Loosely correlated
-1.05%
SYK - DXCM
41%
Loosely correlated
-1.54%
NVST - DXCM
40%
Loosely correlated
-0.64%
GKOS - DXCM
39%
Loosely correlated
-0.61%
More

Groups containing DXCM

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DXCM
1D Price
Change %
DXCM100%
-1.03%
Medical/Nursing Services
industry (220 stocks)
7%
Poorly correlated
-0.32%
Health Services
industry (412 stocks)
-1%
Poorly correlated
-0.23%